FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2102647385> ?p ?o ?g. }

• W2102647385 endingPage "1337" @default.
• W2102647385 startingPage "1330" @default.
• W2102647385 abstract "Purpose: We performed this double-blinded, placebo-controlled study to determine the safety and efficacy of l-alanyl-l-glutamine in the prevention of mucositis in patients with head-and-neck cancer. Methods and Materials: Thirty-two patients with head-and-neck cancer were treated with chemoradiotherapy (CRT) (radiotherapy daily up to 70 Gy plus cisplatin/5-fluoruracil once a week) and were asked to participate. Twenty-nine patients received the CRT schedule and were double-blindly assigned to receive either intravenous l-alanyl-l-glutamine 0.4 g/kg weight/day or an equal volume of saline (placebo) during chemotherapy days. Results: Fourteen patients received l-alanyl-l-glutamine and 15 received placebo. Mucositis was assessed by the Objective Mucositis Score (OMS) and the World Health Organization (WHO) grading system. There was a significant difference in incidence of mucositis developed in patients receiving placebo compared with those who received l-alanyl-l-glutamine (p = 0.035). The number of patients with severe objective mucositis (OMS >1.49) was higher in the placebo group compared with the l-alanyl-l-glutamine group (67% vs. 14%, p = 0.007). l-alanyl-l-glutamine patients experienced less pain (three highest Numeric Rating Scale scores of 1.3/10 vs. 6.3/10 respectively, p = 0.008) and need for feeding tubes (14% vs. 60% respectively, p = 0.020) compared with placebo patients. No adverse effects related to the drug or the infusions were noted in either group. Conclusion: For patients with head-and-neck cancer receiving CRT, intravenous l-alanyl-l-glutamine may be an effective preventive measure to decrease the severity of mucositis. Purpose: We performed this double-blinded, placebo-controlled study to determine the safety and efficacy of l-alanyl-l-glutamine in the prevention of mucositis in patients with head-and-neck cancer. Methods and Materials: Thirty-two patients with head-and-neck cancer were treated with chemoradiotherapy (CRT) (radiotherapy daily up to 70 Gy plus cisplatin/5-fluoruracil once a week) and were asked to participate. Twenty-nine patients received the CRT schedule and were double-blindly assigned to receive either intravenous l-alanyl-l-glutamine 0.4 g/kg weight/day or an equal volume of saline (placebo) during chemotherapy days. Results: Fourteen patients received l-alanyl-l-glutamine and 15 received placebo. Mucositis was assessed by the Objective Mucositis Score (OMS) and the World Health Organization (WHO) grading system. There was a significant difference in incidence of mucositis developed in patients receiving placebo compared with those who received l-alanyl-l-glutamine (p = 0.035). The number of patients with severe objective mucositis (OMS >1.49) was higher in the placebo group compared with the l-alanyl-l-glutamine group (67% vs. 14%, p = 0.007). l-alanyl-l-glutamine patients experienced less pain (three highest Numeric Rating Scale scores of 1.3/10 vs. 6.3/10 respectively, p = 0.008) and need for feeding tubes (14% vs. 60% respectively, p = 0.020) compared with placebo patients. No adverse effects related to the drug or the infusions were noted in either group. Conclusion: For patients with head-and-neck cancer receiving CRT, intravenous l-alanyl-l-glutamine may be an effective preventive measure to decrease the severity of mucositis." @default.
• W2102647385 created "2016-06-24" @default.
• W2102647385 creator A5000278206 @default.
• W2102647385 creator A5009223045 @default.
• W2102647385 creator A5015823368 @default.
• W2102647385 creator A5018931403 @default.
• W2102647385 creator A5021730241 @default.
• W2102647385 creator A5026119359 @default.
• W2102647385 creator A5036360929 @default.
• W2102647385 creator A5040647356 @default.
• W2102647385 creator A5059389744 @default.
• W2102647385 creator A5073525694 @default.
• W2102647385 creator A5075688242 @default.
• W2102647385 date "2006-08-01" @default.
• W2102647385 modified "2023-10-01" @default.
• W2102647385 title "Double-blinded, placebo-controlled trial on intravenous l-alanyl-l-glutamine in the incidence of oral mucositis following chemoradiotherapy in patients with head-and-neck cancer" @default.
• W2102647385 cites W1964699291 @default.
• W2102647385 cites W1967208836 @default.
• W2102647385 cites W1976810006 @default.
• W2102647385 cites W1976971060 @default.
• W2102647385 cites W1985132942 @default.
• W2102647385 cites W1986497986 @default.
• W2102647385 cites W2011900402 @default.
• W2102647385 cites W2018544102 @default.
• W2102647385 cites W2022832543 @default.
• W2102647385 cites W2029633523 @default.
• W2102647385 cites W2030471133 @default.
• W2102647385 cites W2042560813 @default.
• W2102647385 cites W2054341520 @default.
• W2102647385 cites W2067758224 @default.
• W2102647385 cites W2075574715 @default.
• W2102647385 cites W2076668534 @default.
• W2102647385 cites W2092657535 @default.
• W2102647385 cites W2095295709 @default.
• W2102647385 cites W2131506624 @default.
• W2102647385 cites W2144950446 @default.
• W2102647385 cites W2315615415 @default.
• W2102647385 cites W2331395194 @default.
• W2102647385 cites W2473007747 @default.
• W2102647385 cites W2079560916 @default.
• W2102647385 doi "https://doi.org/10.1016/j.ijrobp.2006.03.042" @default.
• W2102647385 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16765532" @default.
• W2102647385 hasPublicationYear "2006" @default.
• W2102647385 type Work @default.
• W2102647385 sameAs 2102647385 @default.
• W2102647385 citedByCount "96" @default.
• W2102647385 countsByYear W21026473852012 @default.
• W2102647385 countsByYear W21026473852013 @default.
• W2102647385 countsByYear W21026473852014 @default.
• W2102647385 countsByYear W21026473852015 @default.
• W2102647385 countsByYear W21026473852016 @default.
• W2102647385 countsByYear W21026473852017 @default.
• W2102647385 countsByYear W21026473852018 @default.
• W2102647385 countsByYear W21026473852019 @default.
• W2102647385 countsByYear W21026473852020 @default.
• W2102647385 countsByYear W21026473852021 @default.
• W2102647385 countsByYear W21026473852022 @default.
• W2102647385 countsByYear W21026473852023 @default.
• W2102647385 crossrefType "journal-article" @default.
• W2102647385 hasAuthorship W2102647385A5000278206 @default.
• W2102647385 hasAuthorship W2102647385A5009223045 @default.
• W2102647385 hasAuthorship W2102647385A5015823368 @default.
• W2102647385 hasAuthorship W2102647385A5018931403 @default.
• W2102647385 hasAuthorship W2102647385A5021730241 @default.
• W2102647385 hasAuthorship W2102647385A5026119359 @default.
• W2102647385 hasAuthorship W2102647385A5036360929 @default.
• W2102647385 hasAuthorship W2102647385A5040647356 @default.
• W2102647385 hasAuthorship W2102647385A5059389744 @default.
• W2102647385 hasAuthorship W2102647385A5073525694 @default.
• W2102647385 hasAuthorship W2102647385A5075688242 @default.
• W2102647385 hasConcept C120665830 @default.
• W2102647385 hasConcept C121332964 @default.
• W2102647385 hasConcept C126322002 @default.
• W2102647385 hasConcept C141071460 @default.
• W2102647385 hasConcept C142724271 @default.
• W2102647385 hasConcept C185592680 @default.
• W2102647385 hasConcept C197934379 @default.
• W2102647385 hasConcept C204787440 @default.
• W2102647385 hasConcept C27081682 @default.
• W2102647385 hasConcept C2776530083 @default.
• W2102647385 hasConcept C2776694085 @default.
• W2102647385 hasConcept C2778424827 @default.
• W2102647385 hasConcept C2778496288 @default.
• W2102647385 hasConcept C2779349466 @default.
• W2102647385 hasConcept C42219234 @default.
• W2102647385 hasConcept C509974204 @default.
• W2102647385 hasConcept C515207424 @default.
• W2102647385 hasConcept C55493867 @default.
• W2102647385 hasConcept C61511704 @default.
• W2102647385 hasConcept C71924100 @default.
• W2102647385 hasConcept C90924648 @default.
• W2102647385 hasConceptScore W2102647385C120665830 @default.
• W2102647385 hasConceptScore W2102647385C121332964 @default.
• W2102647385 hasConceptScore W2102647385C126322002 @default.
• W2102647385 hasConceptScore W2102647385C141071460 @default.
• W2102647385 hasConceptScore W2102647385C142724271 @default.
• W2102647385 hasConceptScore W2102647385C185592680 @default.
• W2102647385 hasConceptScore W2102647385C197934379 @default.

• next